Outsized Ventures

Magdrive Limited, established in 2019 and headquartered in Didcot, United Kingdom, specializes in developing advanced spacecraft propulsion systems tailored for small satellites. The company's innovative technology features a plasma thruster that combines the high thrust of chemical rockets with the high efficiency of electric thrusters. This dual capability allows spacecraft to travel faster and longer while reducing propellant requirements, thereby lowering costs and improving fuel efficiency for satellite maneuvers and missions in Low Earth Orbit (LEO).

Biorce is a pioneering HealthAI startup dedicated to revolutionizing drug development via artificial intelligence. The company's core product is a clinical AI assistant, designed to streamline clinical trials, enhancing both speed and cost efficiency. This platform grants access to clinical data, empowering researchers to accelerate medical advancements and ultimately improve patient outcomes.

MixRift is a gaming company focused on creating interactive and mixed-reality gaming experiences. The company operates a gaming studio dedicated to the development of immersive entertainment games, particularly in the genres of survival and puzzles. By leveraging innovative technology, MixRift aims to enhance the gaming experience by seamlessly bridging the gap between virtual and real worlds, offering players unique and engaging gameplay.

Julienne Bruno is a producer of plant-based food products that focus on creating innovative alternatives to traditional cheese and salami. Utilizing naturally sourced ingredients such as fermented legumes and slow-roasted vegetables, the company aims to transform the landscape of alternative food options. By offering dairy-free and meat-free items, Julienne Bruno enables consumers to explore new culinary experiences while enjoying nutritious and flavorful dishes. The brand is committed to promoting a healthier lifestyle through its unique and wholesome food offerings.

Emitwise Ltd is a London-based company that specializes in developing software solutions for carbon footprint measurement and management. Established in 2019, Emitwise offers a platform that utilizes advanced AI technology to enable businesses to automatically track, report, and reduce their carbon emissions across operations and supply chains. The solution provides real-time insights and tools designed to help organizations implement effective strategies to meet sustainability targets and respond to the climate emergency. By streamlining carbon accounting and offering actionable data, Emitwise aims to facilitate the transition to a net-zero carbon world, equipping companies with the necessary resources to drive meaningful emissions reductions.

Molecule.one is a biotechnology company that specializes in artificial intelligence-driven software for chemical synthesis. Its m1 platform enhances the preclinical pipeline by maximizing efficiency in chemistry-related processes. The company’s software predicts the likelihood of synthesizing novel small molecules and automates significant portions of the manual work involved in synthesis design. By leveraging vast datasets that exceed human processing capabilities, Molecule.one enables clients to concentrate on drug candidates that are not only cost-effective to synthesize but also have a higher probability of success in the development process. This integration of AI into chemical synthesis represents a significant advancement in the field, streamlining workflows for bench chemists, data scientists, and computational chemists alike.

Treos Bio, Inc. is a clinical-stage biotechnology company focused on developing precision cancer immunotherapies that are tailored to individual patients' genetic profiles. Founded in 2013 and headquartered in San Francisco, California, Treos Bio employs advanced computational data science and proprietary biomarkers to create targeted immunotherapies. Its product offerings include the PEPI test, which analyzes genetic data from saliva or blood samples to predict a person’s immune response to specific antigens. The company also produces PolyPEPI immunotherapy vaccines designed for various cancers, including melanoma, lung, breast, colorectal, ovarian, glioma, and leukemia. Additionally, Treos Bio offers the PolyPEPI CDx companion diagnostic test to determine the effectiveness of treatments for individual patients, as well as a Melanoma Screening Test that identifies individuals at high risk for melanoma based on genetic information.

Hoxton Farms, based in London, UK, specializes in producing real animal fat without the use of animals. The company employs cell biology and advanced mathematical modeling to cultivate purified animal fat in bioreactors, catering primarily to the meat alternatives industry. This innovative approach enables the creation of cruelty-free fat that can be utilized not only in meat alternatives but also in other sectors such as bakery, confectionery, and cosmetics. By focusing on sustainable and ethical production methods, Hoxton Farms aims to transform the way fat is sourced and used in various products.

Magdrive Limited, established in 2019 and headquartered in Didcot, United Kingdom, specializes in developing advanced spacecraft propulsion systems tailored for small satellites. The company's innovative technology features a plasma thruster that combines the high thrust of chemical rockets with the high efficiency of electric thrusters. This dual capability allows spacecraft to travel faster and longer while reducing propellant requirements, thereby lowering costs and improving fuel efficiency for satellite maneuvers and missions in Low Earth Orbit (LEO).

Living Optics Limited is a company focused on designing and developing compact hyperspectral imaging cameras and related software, aimed at revolutionizing the imaging market. Founded in 2019 and headquartered in Oxford, United Kingdom, with additional offices in Taiwan, Living Optics seeks to make hyperspectral imaging accessible for a variety of consumer products, medical devices, and industrial applications. The company's innovative technology captures data that is typically invisible to the human eye and conventional cameras, offering an affordable and portable solution for users, including computer vision developers and scientists. This allows clients to integrate spectral imaging data into new applications and research, broadening the potential uses of their groundbreaking imaging technology.

Hoxton Farms, based in London, UK, specializes in producing real animal fat without the use of animals. The company employs cell biology and advanced mathematical modeling to cultivate purified animal fat in bioreactors, catering primarily to the meat alternatives industry. This innovative approach enables the creation of cruelty-free fat that can be utilized not only in meat alternatives but also in other sectors such as bakery, confectionery, and cosmetics. By focusing on sustainable and ethical production methods, Hoxton Farms aims to transform the way fat is sourced and used in various products.

Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Fathom Radiant was created on the premise of applying first-principles thinking to create technology capable of enabling artificial general intelligence for the benefit of all. The company does not believe that the beneficial advancement of AI is unavoidable, and Faathom believes that as a company offering a critical layer in the AI technology stack, we can make a difference in how securely advanced AI systems are built and deployed.

Phenomic AI Inc. is a biotechnology company based in Toronto, Canada, focused on accelerating drug discovery and developing therapies for cancer. Founded in 2017, Phenomic AI has created an innovative drug discovery platform that leverages artificial intelligence and computer vision to analyze phenotypic assays. This platform enables the examination of complex disease models, including high-content co-culture and three-dimensional assays, allowing pharmaceutical companies to discover and optimize therapeutics more efficiently. By specializing in targeting tumor stroma, Phenomic AI aims to enhance the drug development process, making it easier for researchers to identify effective medicines.

Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.

Temporall is a developer of an AI-driven workplace intelligence platform that assists organizations in enhancing their effectiveness. By aggregating and connecting fragmented data across a company, Temporall employs artificial intelligence and machine learning techniques to analyze this information and extract valuable insights. The platform is designed to support leadership teams by offering expert recommendations and comprehensive reporting, ultimately guiding clients toward performance optimization. Positioned at the intersection of enterprise software and organizational science, Temporall combines advanced technology with human expertise to address the strategic needs of its clients.